scholarly journals Correlation of Disease Activity and Quality of Life of Patients with Psoriasis after Narrow-band Ultraviolet B Therapy

Folia Medica ◽  
2020 ◽  
Vol 62 (1) ◽  
pp. 89-93
Author(s):  
Lyubomir A. Dourmishev ◽  
Karolina Lyubomirova
Keyword(s):  
Quality Of Life ◽  
Narrow Band ◽  
Life Quality ◽  
Clinical Effectiveness ◽  
Symptom Assessment ◽  
Severity Index ◽  
Ultraviolet B ◽  
Effective Treatment Option ◽  
Pasi Score

Introduction: Treatment with ultraviolet light is a well-established and effective treatment option for mild to moderate psoriasis. The aims of the study were to measure the psoriasis area and severity index (PASI) reduction after narrow-band ultraviolet B (NB UVB) therapy, to evaluate the quality of life before and after treatment using the dermatology life quality index (DLQI), and to compare the clinical effectiveness with quality of life improvement.   Material and methods: Twenty two patients (13 male and 9 female patients), aged between 21 to 70 years (mean age 40±14.65 years) were enrolled in the study. NB UVB treatment was performed with 10 to 25 (mean 18.5; SD 3.39) procedures with cumulative doses of 5 to 19.4 J/cm2. The baseline median PASI score was 20.027 which decreased after therapy to 11.11. More than PASI 50% reduction was achieved in 40.91% of the patients after at least 6 weeks of treatment and the results are highly statistically significant. Quality of life (QoL) assessed using DLQI was found moderately affected by disease pretreatment. NB UVB therapy significantly increased DLQI score in spectrum of ‘symptoms and feelings’ and ‘treatment’.   Discussion: The PASI score reduction that we observed after NB-UVB therapy is consistent with the results reported by other authors. Baseline DLQI scores were indicative of moderate QoL impairments associated with disease. At the same time, the reduction of the DLQI index corresponding to improved QoL correlated with the objective clinical symptom assessment.    Conclusion: Our data suggest that DLQI and PASI indexes are important complementary methods for comprehensive health assessment of patients with psoriasis. 

scholarly journals An Observational Study to Evaluate Quality of Life in Patients with Melasma in A Tertiary Level Hospital of Pokhara

2021 ◽  
Vol 19 (1) ◽  
pp. 37-41
Author(s):  
Prajwal Pudasaini ◽  
Saraswoti Neupane
Keyword(s):  
Quality Of Life ◽  
Age Of Onset ◽  
Life Quality ◽  
Sun Exposure ◽  
Severity Index ◽  
Cross Sectional ◽  
Medical College ◽  
The Mean ◽  
Hormonal Therapies

Introduction: Melasma is an acquired hyper melanosis that becomes more pronounced after sun exposure. Centro facial which is the commonest pattern followed by Malar and Mandibular are three clinical patterns of Melasma. Genetic influences, exposure to UV radiation, pregnancy, hormonal therapies, contribute to the pathogenesis of melasma. Melasma may considerably have significant effect on quality of life of patients.   Objectives: The present study was conducted to evaluate the effects of melasma in quality of life (QoL) in the form of DLQI (Dermatology Life Quality Index) and severity of melasma according to Melasma Area and Severity Index (MASI).   Materials and Methods: This is a hospital based cross-sectional prospective study conducted in 193 Melasma patients in the Department of Dermatology, Venereology and Leprology, Gandaki Medical College and Teaching Hospital, Pokhara from November 2018 to November 2019. MASI score was calculated and the patients were provided with a Nepali version of DLQI to fill up.   Results: This study included 193 patients. Mean age of patients with melasma was 29.4 ± 8.5 years with maximum reported age of 59 years. The Mean age of onset of disease was 26.5 years. The Mean age of onset of disease had little impact on DLQI. The mean DLQI score was 10.9 ± 5.9, thus indicating “very large effect on patient’s life”. The mean MASI score was 6.6 ± 5.2. It was found that there was no correlation between severity of disease and DLQI scores (p=0.317) Conclusion: Melasma commonly affected females during second and third decades of life. It had a very large effect on patient’s life as assessed by DLQI.    

The Effect of Psoriasis on Patients' Quality of Life and Improvements Associated with Alefacept Therapy

2004 ◽  
Vol 8 (2_suppl) ◽  
pp. 20-25
Author(s):  
Alan Menter
Keyword(s):  
Quality Of Life ◽  
Unmet Need ◽  
Life Quality ◽  
Severity Index ◽  
Biologic Agent ◽  
Number Of Patients ◽  
Negative Effect ◽  
Clinical Measures

Patients with psoriasis may experience impaired psychosocial mental status regardless of their objectively defined disease severity. The objective clinical measures of disease that are commonly used to evaluate a patient's psoriasis fail to take into account the effect of psoriasis on patients' quality of life (QOL). As a result, a significant number of patients are dissatisfied with conventional treatments and are searching for new options. A high unmet need for effective and safe long-term therapies that can also improve patients' QOL exists in psoriasis. Alefacept, a selective biologic agent specifically designed for the treatment of psoriasis, provides improvement in both the physical (as measured by the Psoriasis Area and Severity Index) and mental (as measured by the Dermatology Life Quality Index) aspects of the disease. Additionally, alefacept is extremely well tolerated, with no negative effect on QOL, and the improvement in QOL is maintained off-treatment, which is consistent with its remittive effects on the disease. Alefacept helps fulfill the needs of psoriasis patients by providing efficacy, safety, off-treatment remissions, and improvement in QOL.

Psoriasis: Wechsel der Medikamentenklasse bei Nichtansprechen?

2020 ◽  
Vol 8 (1) ◽  
pp. 16-18 ◽  
Author(s):  
Sandra Philipp
Keyword(s):  
Quality Of Life ◽  
Severity Index ◽  
Biologic Agents ◽  
Efficacy And Safety ◽  
Serious Adverse Events ◽  
Psoriasis Area Severity Index ◽  
Drug Survival ◽  
Quality Of Life Index ◽  
Pasi Score

Background: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported. Methods: This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients. Results: A total of 21 patients unresponsive to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. Ustekinumab was effective in reducing disease severity, with significant improvements of both psoriasis area severity index (PASI) and dermatology quality of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, were detected (p<0.05), achieving PASI 50, 75, and >90 responses in 93.8, 87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab treatment because of inefficacy, and failure of multiple biologic agents (>2) seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were reported while 38.1% of patients experienced mild AEs. Conclusion: Ustekinumab was safe and effective in treating patients unresponsive to secukinumab.

scholarly journals Scalp Psoriasis and Biologic Agents: A Review

2021 ◽  
pp. 1-10
Author(s):  
Ilias Papadimitriou ◽  
Katerina Bakirtzi ◽  
Alexander Katoulis ◽  
Dimitrios Ioannides
Keyword(s):  
Quality Of Life ◽  
Plaque Psoriasis ◽  
Psychological Impact ◽  
Life Quality ◽  
Severity Index ◽  
Scalp Psoriasis ◽  
Significant Regression ◽  
Term Maintenance

Scalp-localized psoriasis is common among patients affected with plaque psoriasis, rendering its treatment exceedingly difficult. Furthermore, the symptoms caused by the disease like scaling, erythema, and pruritus, among others, pose a major psychological impact and a significant regression in the quality of life of the affected patients. Biologics have proved their efficacy in assuaging the symptoms, in terms of Psoriasis Area and Severity Index (PASI) reduction, and offering optimum quality of life, by decreasing the Dermatology Life Quality Index (DLQI) in the patients suffering from plaque psoriasis. Herein, we sought to evaluate the efficacy of biologics and small molecules in controlling the symptoms and their ability to offer long-term maintenance in the disease activity.

scholarly journals Quality of life in patients with melasma in Turkish women

2017 ◽  
Vol 9 (2) ◽  
Author(s):  
Hacer Uyanikoglu ◽  
Mustafa Aksoy
Keyword(s):  
Quality Of Life ◽  
Severe Disease ◽  
Life Quality ◽  
Severity Index ◽  
Older Individuals ◽  
Turkish Women ◽  
Moderate Disease ◽  
Study Population ◽  
The Impact

The aim of this study was to determine the impact of melasma on quality of life (QoL) using the dermatology life quality index (DLQI) questionnaire in a group of outpatients. This study is questionnairebased. A total of 101 Turkish women suffering from melasma, who themselves were able to understand and complete the Turkish version of the DLQI questionnaire, were enrolled. This questionnaire included 10 questions; each of each was scored on a scale of 0-3, with a maximum score of 30. The data were analyzed after the results had been collated and the higher the DLQI score, the poorer the QoL. The participants’ mean age was 29.53±6.87 years, and mean DLQI score was 6.02±4.94. When we divided the participants into two subgroups according to age, the DLQI scores for younger and older individuals were 7.44±4.99 and 4.33±4.36, respectively (P=0.001). When the melasma area and severity index (MASI) score was used, participants with mild and moderate disease had mean DLQI scores of 5.80±4.72 and 7.11±5.90, respectively. No patient had severe disease. Melasma might affect the participants’ QoL, especially that of the younger individuals, in our study population.

scholarly journals Assessment of Quality of Life in a Sample of Iraqi Patients with Psoriasis.

2020 ◽  
Vol 29 (2) ◽  
pp. 161-168
Author(s):  
Sarah H. Abdulridha ◽  
Dheyaa J. Kadhim ◽  
Sarmad A. Abdul Razzak
Keyword(s):  
Quality Of Life ◽  
Negative Impact ◽  
Life Quality ◽  
Severity Index ◽  
Monthly Income ◽  
Psychosocial Effects ◽  
Significant Deterioration ◽  
Cross Sectional ◽  
The Mean

Psoriasis is a dermatological, chronic, immune-mediated condition. Psoriasis symptoms are not associated with physical burden only, but it may also have psychosocial effects on patients, diminished cognitive control, poor body image and impairments in everyday life. The value of quality of life is important since improving it is the principal goal for non-curative disease. The aim of the current study was to evaluate quality of life in a sample of Iraqi patients with psoriasis. This study is a cross-sectional study that involved 300 already diagnosed psoriasis patients who attended to the center of Dermatology and Venereology, Medical City/Baghdad. The mean age of patients was (35.156 ±10.549 years). The Arabic version of Dermatology Life Quality Index was used to assess quality of life.  The mean total score is 11.29± 5.45 and the majority of the patients (53.7%) had a total score of more than 10, which indicates a significant deterioration in patients’ quality of life. The greatest impact was found in symptoms and feelings (mean = 1.66 ± 0.75) while the lowest impact was noted in personal relationships (0.51± 0.65). Increasing age and monthly income as well as vulgaris type of psoriasis associated significantly better quality of life. While Psoriasis Area and Severity Index associated significantly worse quality of life. In conclusion, psoriasis exerts significant, negative impact on patients’ quality of life, especially among those with younger age, lower monthly income, high disease activity, and types of psoriasis other than vulgaris.   

Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children

Dermatology ◽  
2019 ◽  
Vol 236 (3) ◽  
pp. 191-198 ◽  
Author(s):  
Nawaf AlMutairi ◽  
Tarek Nour
Keyword(s):  
Pediatric Patients ◽  
Life Quality ◽  
Severity Index ◽  
Inflammatory Disorder ◽  
Open Label ◽  
Multicenter Trials ◽  
Pasi Score ◽  
Open Label Trial ◽  
Underlying Inflammation

Introduction: Psoriasis is a chronic, multifactorial, inflammatory disorder, with an estimated prevalence of 0.71% in children. The commonly used therapeutic agents target the underlying inflammation. Tofacitinib has demonstrated efficacy in adult psoriasis. Aim: To study the efficacy, safety, and tolerability of tofacitinib in pediatric patients with moderate to severe chronic plaque psoriasis. Methods: The study included children aged between 8 and 17 years, with moderate to severe psoriasis, given tofacitinib 5 mg orally twice daily for at least 36 weeks. The clinical response was estimated using the Psoriasis Area and Severity Index (PASI) score, Physician’s Global Assessment (PGA), and the Children’s Dermatology Life Quality Index (CDLQI). The incidence and severity of adverse events (AEs) were meticulously recorded in each case. Results: A total of 47 patients, with a median age of 12.3 years, completed the study. At week 12, 55.32% achieved PASI 75, and 70.21% at week 36. PGA of clear or almost clear responses at week 12 were 59.57 and 65.96%, ­respectfully, at week 36. Relatively few and mostly minor ­adverse effects were noted. No severe AEs were reported. ­Conclusion: The treatment with tofacitinib was safe and well tolerated, and led to significant improvement of their disease and quality of life as reflected in CDLQI scores. However, the results need to be validated in larger multicenter trials.

scholarly journals Hand Eczema: Quality of Life and Disease Severity in an Outpatient Portuguese Population

2018 ◽  
Vol 76 (2) ◽  
pp. 137-142
Author(s):  
Rui Pedro Santos ◽  
Laura Igreja ◽  
Cristina Resende ◽  
Teresa Pereira ◽  
Celeste Brito
Keyword(s):  
Quality Of Life ◽  
Disease Severity ◽  
Life Quality ◽  
Severity Index ◽  
Hand Eczema ◽  
Common Disease ◽  
Female Predominance ◽  
Duration Of Disease ◽  
A Prospective Study

Introduction: Hand eczema is a very common disease with a significant social and occupational impact.Objectives: To characterize a Portuguese outpatient population with hand eczema; to evaluate the impairment of the disease in quality of life (QoL); to relate the disease severity with QoL.Methods: The authors designed a prospective study. Information about atopy, psoriasis, occupational exposure and duration of disease, was recorded. The QoL was assessed by the DLQI questionnaire (Dermatology Life Quality Index) and the severity was assessed using the hand eczema severity index (HECSI). All participants were patch tested.Results: Eighty-five patients were included with a female predominance (78.8%). The median DLQI was 9.0. We found statistically significant differences in the variable HECSI between genders with greater impact in males. A significant positive correlation was found between HECSI and DLQI. DLQI and HECSI were independent of atopy, psoriasis or etiology. Increasing age significantly affects DLQI but not HECSI.Conclusions: Hand eczema has a significant impact in QoL. Although the disease is more prevalent among women it was found to be of greater severity among men. The QoL seems to be influenced by disease severity and increasing age but it was independent of the other studied variables.

scholarly journals MELASMA;

2017 ◽  
Vol 24 (12) ◽  
pp. 1899-1903
Author(s):  
Wajid Ali Akhunzada ◽  
Naima Luqman ◽  
Asima Luqman ◽  
Muhammad Khalid ◽  
Sultana Jam
Keyword(s):  
Quality Of Life ◽  
Negative Impact ◽  
Life Quality ◽  
Severity Index ◽  
The Body ◽  
Emotional Wellbeing ◽  
Dermatology Department ◽  
Social And Emotional ◽  
The Impact

Introduction: Melasma is an acquired, chronic, recurrent symmetricalhypermelanosis which is characterized by brown patches of variable darkness on sun exposedareas of the body primarily on the face.1,2 Melasma is more common in Asians and in peoplewho live in locations that receive high intensity UV radiation.3,4 Melasma is a skin disease thatsignificantly affects social and emotional wellbeing of the patients as well as their Quality of Life(QoL). Objectives: To find out the impact of melasmaon quality of life of the patients. StudyDesign: It is a descriptive study and the sample (patients), were selected through convenientsampling. Place and Duration of study: The study was conducted in the department ofpsychiatry & Dermatology department of Bahawal Vicortoria Hospital, Bahawalpur from July toDecember 2016. Material and Methods: Hundred patients having melasma including 11 malesand 89 females from both departments were included in the study. Two questionnaires wereapplied for measuring target variables, these were (i) Dermatology Life Quality Index to assessthe effect of melasma on quality of life (DLQI) and (ii) Melasma Area Severity Index (MASI) todetermine the severity of melasma. Results: The study included 100 patients of which 89 werefemales while 11 were males. Mean age of the patients was 27+6. Regarding the educationalstatus of patients, the majority (36%) were graduates and 16% had a Masters degree. Of thesepatients, 53% were unmarried while 47% were married. Mean DLQI was slightly higher forfemale patients (13.48) as compared to male patients (12.82). Mean MASI was also higherin females (15.26) as compared to males which was (14.39). Conclusions: Melasma causessignificant negative impact on quality of life especially in women.

scholarly journals Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients

2020 ◽  
Vol 9 (9) ◽  
pp. 2684
Author(s):  
Simona Tavecchio ◽  
Luisa Angileri ◽  
Francesco Pozzo Giuffrida ◽  
Francesca Germiniasi ◽  
Angelo Valerio Marzano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Clinical Manifestations ◽  
Life Quality ◽  
Daily Practice ◽  
Severity Index ◽  
Efficacy And Safety

Background: The clinical features of adult-onset atopic dermatitis (AD) are heterogeneous and the diagnosis can be a challenge. A new biologic drug (dupilumab) has been approved for moderate to severe AD in adult patients. The efficacy and safety have been demonstrated in clinical trials, but these studies do not reflect conditions in daily practice and do not consider the different clinical manifestations of AD. Objectives: Analyzing the dupilumab activity in a real-world setting and comparing its efficacy on different AD phenotypes. Methods: We retrospectively evaluated 221 AD patients treated with dupilumab, stratified into six clinical phenotypes: classic, generalized eczema inflammatory and lichenoid patterns, prurigo, nummular eczema, and erythroderma. At baseline and at weeks 4, 16, and 52, the disease severity was assessed through the Eczema Area and Severity Index (EASI) and the quality of life was assessed through the Dermatology Life Quality Index (DLQI) questionnaire, Peak Pruritus Numerical Rating Scale (itch NRS), and Peak Sleep NRS. Results: We found a significant improvement after 16 weeks of treatment (p < 0.0001) in all six phenotypes for all the assessed scores mentioned above, persisting up to week 52. The best improvement was seen in the more severe phenotypes, particularly the erythrodermic one. Conclusions: The present study confirmed the efficacy and safety of dupilumab in the treatment of severe AD. Its strength was in the stratification of AD patients in six different phenotypes based on their clinical presentation, all of whom markedly improved in terms of both clinically evident and reported symptoms, as well as their quality of life.

Sign in / Sign up

Export Citation Format

Share Document